A collaboration led by scientists at Tokyo University of Agriculture and Technology (TUAT), Japan, has discovered a novel amyloid protein from canine mammary tumors. This amyloid protein, α-S1 casein, normally plays a vital role in the transport of calcium phosphate as a milk protein that provides infant nutrition, but its involvement in disease was unknown. In this study, they have shown for the first time that α-S1 casein can cause amyloidosis in vivo and clarified the detailed mechanism of amyloid formation.
The researchers published their results on Jan 21st in Veterinary Pathology.
Amyloidosis is a disease group in which amyloid, generated by misfolding of host proteins, deposits in several organs. To control the onset and progression of amyloidosis, it is necessary to understand the overall picture of the complex pathogenesis of the disease. However, an integrated understanding has not been established, and the development of definitive treatments has stalled.
"Amyloidosis associated with canine mammary tumors was first reported in Jul 1985, but the amyloid precursor protein was unknown. Since I was born in July 1985 and am the same age, I had a sense of familiarity with this disease," said Tomoaki Murakami, DVM, PhD, the first and corresponding author on the paper and Associate Professor in Laboratory of Veterinary Toxicology at TUAT. They first performed mass spectrometry-based proteomic analysis on five dogs with mammary tumor-associated amyloidosis and identified α-S1-casein as an amyloid precursor protein. "This discovery was a surprise because the amyloidogenicity of α-S1 casein has been unknown, and it was rather thought that its chaperone function regulated amyloid formation of other milk proteins, such as α-S2 casein and κ-casein."
Gene analysis revealed that expression of α-S1 casein was elevated dozens of times in individuals with amyloidosis than in those without amyloidosis. By further analysis using mass spectrometry, they noticed that N-terminal disordered region was lost in α-S1-casein in amyloid deposits. "These results clearly support that α-S1 casein acquires its amyloid-forming ability through overexpression and truncation of the N-terminal disordered region," said Murakami. They next cultured recombinant proteins of N-terminal-truncated α-S1-casein in vitro and found their amyloid formation.
"Since α-S1-casein is also expressed in the mammary glands of humans, we felt it was necessary to assess the risk in humans," said Murakami. They therefore confirmed that synthetic peptides derived from human α-S1-casein form amyloid in vitro and found that α-S1-casein-induced amyloidosis can occur in humans.
"Research on animal diseases is essential not only for maintaining the health of livestock and pets, but also for gaining a deeper understanding of human pathology. In this study, we discovered amyloidosis in dogs, which has not yet been discovered in humans, and also clarified the potential risk of the disease in humans based on in vitro experiments. We expect that our findings will provide useful information for predicting the possible occurrence of amyloidosis in humans," Murakami added.
